Outcomes of CAR-T and alloHCT
| Characteristic . | CAR-T . | alloHCT . |
|---|---|---|
| CRS grade 1-5, no. (%) | 149 (82.3) | N/A |
| CRS grade 3-5, no. (%) | 18 (9.9) | N/A |
| Neurotoxicity grade 1-4, no. (%) | 112 (61.9) | N/A |
| Neurotoxicity grade 3-4, no. (%) | 38 (20.9) | N/A |
| Neutrophil recovery, % (95% CI) | ||
| Day 28 | 89.7 (84.7-93.8) | 96.8 (94.8-98.3) |
| Platelet recovery, % (95% CI) | ||
| Day 100 | 86.7 (81.2-91.4) | 92.1 (89.2-94.6) |
| Grade 2-4 acute GVHD, % (95% CI) | ||
| Day 180 | N/A | 28.7 (18.9-39.7) |
| Grade 3-4 acute GVHD, % (95% CI) | ||
| Day 180 | N/A | 8.2 (3.0-15.6) |
| Chronic GVHD, % (95% CI) | ||
| 1 y | N/A | 35.6 (30.9-40.4) |
| OS, % (95% CI) | ||
| 1 y | 73.4 (66.4-79.9) | 65.6 (60.9-70.2) |
| PFS, % (95% CI) | ||
| 1 y | 55.7 (48.0-63.2) | 53.8 (48.8-58.7) |
| Relapse/progression, % (95% CI) | ||
| 1 y | 39.5 (32.1-47.2) | 26.2 (21.9-30.7) |
| NRM, % (95% CI) | ||
| 1 y | 4.8 (2.1-8.6) | 20.0 (16.2-24.2) |
| Characteristic . | CAR-T . | alloHCT . |
|---|---|---|
| CRS grade 1-5, no. (%) | 149 (82.3) | N/A |
| CRS grade 3-5, no. (%) | 18 (9.9) | N/A |
| Neurotoxicity grade 1-4, no. (%) | 112 (61.9) | N/A |
| Neurotoxicity grade 3-4, no. (%) | 38 (20.9) | N/A |
| Neutrophil recovery, % (95% CI) | ||
| Day 28 | 89.7 (84.7-93.8) | 96.8 (94.8-98.3) |
| Platelet recovery, % (95% CI) | ||
| Day 100 | 86.7 (81.2-91.4) | 92.1 (89.2-94.6) |
| Grade 2-4 acute GVHD, % (95% CI) | ||
| Day 180 | N/A | 28.7 (18.9-39.7) |
| Grade 3-4 acute GVHD, % (95% CI) | ||
| Day 180 | N/A | 8.2 (3.0-15.6) |
| Chronic GVHD, % (95% CI) | ||
| 1 y | N/A | 35.6 (30.9-40.4) |
| OS, % (95% CI) | ||
| 1 y | 73.4 (66.4-79.9) | 65.6 (60.9-70.2) |
| PFS, % (95% CI) | ||
| 1 y | 55.7 (48.0-63.2) | 53.8 (48.8-58.7) |
| Relapse/progression, % (95% CI) | ||
| 1 y | 39.5 (32.1-47.2) | 26.2 (21.9-30.7) |
| NRM, % (95% CI) | ||
| 1 y | 4.8 (2.1-8.6) | 20.0 (16.2-24.2) |
N/A, not applicable.